Brief: Celldex Therapeutics Presents Positive Preclinical Data From TSLP/SCF Bispecific Antibody Program CDX-622 At Immunology2023
15/05/2023 13:07
May 15 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX THERAPEUTICS PRESENTS POSITIVE PRECLINICAL DATA
FROM
TSLP/SCF BISPECIFIC ANTIBODY PROGRAM CDX-622 AT IMMUNOLOGY2023
Source text for Eikon: ID:nGNX86kvqm
Further company coverage: CLDX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials